The Business Research Company Updated 2025 Market Reports have released and offer essential trends and forecasts up to 2034. Early purchase is your competitive edge! LONDON, GREATER LONDON, UNITED KIN ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Combination therapies, such as Regeneron’s Libtayo (cemiplimab) and Merck’s Keytruda (pembrolizumab), are creating new treatment possibilities for advanced skin cancers, including basal cell carcinoma ...

Regeneron Canada, a biotechnology company focused on developing treatments for serious diseases, has reached a pricing and funding agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

“Under the theme “Designing Future Society for Our Lives,” the Expo will address eight key thematic areas focused on global challenges, providing an exceptional platform for PNG to showcase its trade ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...

Objective response rate (ORR) was 31% among 84 Libtayo-treated patients with a median follow-up of 15 months. This included a 6% (n=5) complete and 25% (n=21) partial response rate.